<DOC>
	<DOCNO>NCT00091026</DOCNO>
	<brief_summary>This randomized phase II trial study bevacizumab , gemcitabine , cetuximab see well work compare bevacizumab , gemcitabine , erlotinib treat patient advanced pancreatic cancer . Monoclonal antibody , cetuximab bevacizumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy , gemcitabine , work different way stop tumor cell divide stop grow die . Erlotinib may stop growth tumor cell block enzymes necessary growth . Combining bevacizumab gemcitabine either cetuximab erlotinib may kill tumor cell .</brief_summary>
	<brief_title>Bevacizumab Gemcitabine Combined With Either Cetuximab Erlotinib Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare objective response rate patient advance adenocarcinoma pancreas treat bevacizumab gemcitabine cetuximab v erlotinib . II . Compare toxicity regimens patient . III . Compare median progression-free overall survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center ( University Chicago v ) ECOG performance status ( 0-1 v 2 ) . Patients randomize 1 2 treatment arm . Arm I : Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 ; gemcitabine IV 30 minute day 1 , 8 , 15 ; bevacizumab IV 30-90 minute day 1 15 . Arm II : Patients receive gemcitabine bevacizumab arm I . Patients also receive oral erlotinib daily day 1-5 , 8-12 , 15-26 . In arm , course repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 54-126 patient ( 27-63 per treatment arm ) accrue study within 16 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma pancreas Advanced disease Patients locally advance disease must disease extends outside boundary standard radiation port Not amenable curative surgery radiotherapy Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Pleural effusion ascites consider measurable lesion No CNS disease , include primary brain tumor brain metastasis No tumor invasion duodenum Performance status ECOG 02 More 3 month Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 No history bleed diatheses Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT SGPT ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) INR ≤ 1.5 ( ≤ 3 patient warfarin ) No esophageal varix Creatinine ≤ 1.5 mg/dL Creatinine clearance ≥ 60 mL/min Urine protein &lt; 1+ 24hour urine protein &lt; 500 mg No history recent cerebrovascular accident No clinically significant cardiovascular disease No uncontrolled hypertension No New York Heart Association class IIIV congestive heart failure No serious cardiac arrhythmia require medication No peripheral vascular disease ≥ grade II None follow arterial thromboembolic event within past 6 month : Transient ischemic attack Cerebrovascular accident Unstable angina Myocardial infarction Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study participation HIV negative No significant traumatic injury within past 28 day No gastrointestinal tract disease result inability take oral medication No allergic reaction compound similar bevacizumab , cetuximab , erlotinib ( e.g. , Chinese hamster ovary cell product recombinant humanized antibody ) No serious nonhealing wound , ulcer , bone fracture No active infection require antibiotic No active malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No prior bevacizumab cetuximab No prior vascular endothelial growth factor inhibitors No prior gemcitabine No prior cytotoxic chemotherapy metastatic disease At least 4 week since prior adjuvant chemotherapy ( 6 week mitomycin nitrosoureas ) At least 4 week since prior radiotherapy Must site measurable disease outside radiation port No prior surgical procedure affect absorption More 28 day since prior major surgical procedure open biopsy More 7 day since prior core biopsy No concurrent major surgical procedure No prior erlotinib No prior epidermal growth factor receptor inhibitor At least 30 day since prior investigational drug More 1 month since prior thrombolytic agent Concurrent warfarin low molecular weight heparin allow provide follow criterion meet : Currently therapeutic stable dose INR target range ≤ 3 Patients undergo weekly INR test No evidence active bleed pathological condition carry high risk bleeding ( e.g. , tumor invade adjacent organ esophageal varix ) No concurrent chronic daily therapy aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication know inhibit platelet function No concurrent antiplatelet medication No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy agents No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>